Bruker (NASDAQ:BRKR) Stock Rating Upgraded by The Goldman Sachs Group

Bruker (NASDAQ:BRKR) was upgraded by stock analysts at The Goldman Sachs Group from a “sell” rating to a “neutral” rating in a research report issued on Thursday, Marketbeat.com reports. The firm presently has a $60.00 price objective on the medical research company’s stock. The Goldman Sachs Group’s price objective points to a potential upside of 1.76% from the stock’s current price.

A number of other equities research analysts have also recently commented on BRKR. Citigroup reduced their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Barclays reduced their target price on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Wells Fargo & Company cut their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Finally, TD Cowen decreased their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Stock Up 0.8 %

Shares of NASDAQ:BRKR opened at $58.96 on Thursday. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The business’s 50-day moving average is $59.61 and its 200-day moving average is $63.48. The company has a market capitalization of $8.94 billion, a price-to-earnings ratio of 28.35, a P/E/G ratio of 3.86 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. Bruker’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same period last year, the firm posted $0.74 earnings per share. Equities research analysts predict that Bruker will post 2.4 earnings per share for the current year.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien acquired 100,000 shares of Bruker stock in a transaction on Monday, November 18th. The stock was acquired at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the transaction, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of hedge funds and other institutional investors have recently modified their holdings of BRKR. Tidal Investments LLC bought a new stake in Bruker during the first quarter worth $218,000. Cetera Investment Advisers boosted its holdings in shares of Bruker by 350.0% in the 1st quarter. Cetera Investment Advisers now owns 33,131 shares of the medical research company’s stock worth $3,112,000 after buying an additional 25,768 shares during the last quarter. Cetera Advisors LLC bought a new position in Bruker during the first quarter valued at about $693,000. CWM LLC increased its holdings in Bruker by 165.4% during the second quarter. CWM LLC now owns 4,777 shares of the medical research company’s stock worth $305,000 after buying an additional 2,977 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in Bruker by 2,125.7% during the second quarter. SG Americas Securities LLC now owns 27,465 shares of the medical research company’s stock worth $1,753,000 after buying an additional 26,231 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.